Skip to main content
Erschienen in: Pediatric Nephrology 7/2013

01.07.2013 | Original Article

Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood

verfasst von: Evanthia A. Tsalkidou, Emmanouel Roilides, Stefanos Gardikis, Gregory Trypsianis, Alexandros Kortsaris, Athanasios Chatzimichael, Ioannis Tentes

Erschienen in: Pediatric Nephrology | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Urinary tract infections (UTIs) are encountered frequently in children, and their early diagnosis and treatment are important. This study evaluates the diagnostic value of serum concentrations of lipopolysaccharide-binding protein (LBP), an acute-phase protein, in children with febrile UTI and compares it to those of the total white blood cell count (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6).

Methods

The study population comprised 77 consecutive patients with a first-episode febrile UTI (33 boys) with a median age of 11 months [interquartile range (IQR), 5.5–33 months], 21 healthy controls (11 boys) with a median age of 10 months (IQR, 5–20.5 months) and 58 febrile controls with a fever due to other causes (28 boys) with a median age of 12.5 months (IQR, 7–30 months). LBP, IL-6, PCT, and CRP were measured for both patients and control groups.

Results

The serum levels of LBP (p  <  0.001), CRP (p  <  0.001), PCT (p  =  0.001), IL-6 (p  =  0.002), ESR (p  =  0.020), and WBC (p  <  0.001) were higher in patients with febrile UTI than in the healthy and febrile control groups. The LPB cut-off value for best sensitivity and specificity in patients with febrile UTI was >43.23 mg/l. Furthermore, the area under the receiver operating characteristic curve was significantly greater for LBP than for CRP (p  =  0.014), PCT (p  <  0.001), ESR (p  <  0.001), WBC (p  =  0.002) and IL-6 (p  =  0.006).

Conclusions

The results of this study suggest that the serum LBP concentration constitutes a reliable biologic marker for the diagnosis of a febrile UTI in children.
Literatur
1.
Zurück zum Zitat Saadeh SA, Mattoo TK (2011) Managing urinary tract infections. Pediatr Nephrol 26:1967–1976PubMedCrossRef Saadeh SA, Mattoo TK (2011) Managing urinary tract infections. Pediatr Nephrol 26:1967–1976PubMedCrossRef
2.
Zurück zum Zitat Lutter SA, Currie ML, Mitz LB, Greenbaum LA (2005) Antibiotic resistance patterns in children hospitalized for urinary tract infections. Arch Pediatr Adolesc Med 159:924–928PubMedCrossRef Lutter SA, Currie ML, Mitz LB, Greenbaum LA (2005) Antibiotic resistance patterns in children hospitalized for urinary tract infections. Arch Pediatr Adolesc Med 159:924–928PubMedCrossRef
3.
Zurück zum Zitat Dandona P, Nix D, Wilson MF, Aljada SG, Love J, Assicot M (1994) Procalcitonin increase after endotoxin infection in normal subjects. J Clin Endocrinol Metab 79:1605–1608PubMedCrossRef Dandona P, Nix D, Wilson MF, Aljada SG, Love J, Assicot M (1994) Procalcitonin increase after endotoxin infection in normal subjects. J Clin Endocrinol Metab 79:1605–1608PubMedCrossRef
4.
Zurück zum Zitat Benador N, Siegrist C-A, Gendrel D, Greder C, Sakran W, Halevy R (1998) Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 102:1422–1425 Benador N, Siegrist C-A, Gendrel D, Greder C, Sakran W, Halevy R (1998) Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 102:1422–1425
5.
Zurück zum Zitat Smolkin V, Koren A, Raz R, Colodner R, Sakran W, Halevy R (2002) Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatr Nephrol 17:409–412PubMedCrossRef Smolkin V, Koren A, Raz R, Colodner R, Sakran W, Halevy R (2002) Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatr Nephrol 17:409–412PubMedCrossRef
6.
Zurück zum Zitat Prat C, Dominguez J, Rodrigo C, Giménez M, Azuara M, Jiménez O, Gali N, Ausina V (2003) Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 22:438–442 Prat C, Dominguez J, Rodrigo C, Giménez M, Azuara M, Jiménez O, Gali N, Ausina V (2003) Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 22:438–442
7.
Zurück zum Zitat Gervaix A, Galletto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, Girardin E (2001) Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. Pediatr Infect Dis J 20:507–511 Gervaix A, Galletto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, Girardin E (2001) Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. Pediatr Infect Dis J 20:507–511
8.
Zurück zum Zitat Benson M, Jodal U, Agace W, Hellström M, Mårild S, Rosberg S, Sjöström M, Wettergren B, Jönsson S, Svanborg C (1996) Interleukin (IL)-6 and IL-8 in children with febrile urinary tract infection and asymptomatic bacteriuria. J Infect Dis 174:1080–1084PubMedCrossRef Benson M, Jodal U, Agace W, Hellström M, Mårild S, Rosberg S, Sjöström M, Wettergren B, Jönsson S, Svanborg C (1996) Interleukin (IL)-6 and IL-8 in children with febrile urinary tract infection and asymptomatic bacteriuria. J Infect Dis 174:1080–1084PubMedCrossRef
9.
Zurück zum Zitat Fünfstück R, Franke S, Hellberg M, Ott U, Knöfel B, Straube E, Sommer M, Hacker J (2001) Secretion of cytokines by uroepithelial cells stimulated by Escherichia coli and Citrobacter spp. Int J Antimicrob Agents 17:253–258PubMedCrossRef Fünfstück R, Franke S, Hellberg M, Ott U, Knöfel B, Straube E, Sommer M, Hacker J (2001) Secretion of cytokines by uroepithelial cells stimulated by Escherichia coli and Citrobacter spp. Int J Antimicrob Agents 17:253–258PubMedCrossRef
10.
Zurück zum Zitat Kassir K, Vargas-Shiraishi O, Zaldivar F, Berman M, Singh J (2001) Cytokine profiles of pediatric patients treated with antibiotics for pyelonephritis: potential therapeutic impact. Clin Diagn Lab Immunol 8:1060–1063PubMed Kassir K, Vargas-Shiraishi O, Zaldivar F, Berman M, Singh J (2001) Cytokine profiles of pediatric patients treated with antibiotics for pyelonephritis: potential therapeutic impact. Clin Diagn Lab Immunol 8:1060–1063PubMed
11.
Zurück zum Zitat Roilides E, Papachristou F, Gioulekas E, Tsaparidou S, Karatzas N, Sotiriou J, Tsiouris J (1999) Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-dimercaptosuccinic acid scans in neonates with urinary tract infections. J Infect Dis 180:904–907PubMedCrossRef Roilides E, Papachristou F, Gioulekas E, Tsaparidou S, Karatzas N, Sotiriou J, Tsiouris J (1999) Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-dimercaptosuccinic acid scans in neonates with urinary tract infections. J Infect Dis 180:904–907PubMedCrossRef
12.
Zurück zum Zitat Otto G, Braconier J, Andreasson A, Svanborg C (1999) Interleukin-6 and disease severity in patients with bacteremic and non bacteremic febrile urinary tract infection. J Infect Dis 179:172–179PubMedCrossRef Otto G, Braconier J, Andreasson A, Svanborg C (1999) Interleukin-6 and disease severity in patients with bacteremic and non bacteremic febrile urinary tract infection. J Infect Dis 179:172–179PubMedCrossRef
13.
Zurück zum Zitat Pavcnik-Arnol M, Hojker S, Derganc M (2007) Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 33:1025–1032PubMedCrossRef Pavcnik-Arnol M, Hojker S, Derganc M (2007) Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 33:1025–1032PubMedCrossRef
14.
Zurück zum Zitat Berner R, Fürll B, Stelter F, Dröse J, Müller HP, Schütt C (2002) Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 9:440–445PubMed Berner R, Fürll B, Stelter F, Dröse J, Müller HP, Schütt C (2002) Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 9:440–445PubMed
15.
Zurück zum Zitat Kohara J, Tsuneyoshi N, Gauchat JF, Kimoto M, Fukudome K (2006) Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli. Protein Expr Purif 49:276–283PubMedCrossRef Kohara J, Tsuneyoshi N, Gauchat JF, Kimoto M, Fukudome K (2006) Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli. Protein Expr Purif 49:276–283PubMedCrossRef
16.
Zurück zum Zitat Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D (1997) The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 4:113–116PubMed Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D (1997) The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 4:113–116PubMed
17.
Zurück zum Zitat Pavcnik-Arnol M, Hojker S, Derganc M (2004) Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med 30:1454–1460PubMedCrossRef Pavcnik-Arnol M, Hojker S, Derganc M (2004) Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med 30:1454–1460PubMedCrossRef
18.
Zurück zum Zitat Schröder NW, Heine H, Alexander C, Manukyan M, Eckert J, Hamann L, Göbel UB, Schumann RR (2004) Lipopolysaccharide-binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 173:2683–2691PubMed Schröder NW, Heine H, Alexander C, Manukyan M, Eckert J, Hamann L, Göbel UB, Schumann RR (2004) Lipopolysaccharide-binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 173:2683–2691PubMed
19.
Zurück zum Zitat Blairon L, Wittebole X, Laterre PF (2003) Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to Gram-positive and fungal infections. J Infect Dis 187:287–291PubMedCrossRef Blairon L, Wittebole X, Laterre PF (2003) Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to Gram-positive and fungal infections. J Infect Dis 187:287–291PubMedCrossRef
20.
Zurück zum Zitat Luoto R, Kalliomaki M, Latinen K, Delzene NM, Cani PD, Salminen S, Isolauri E (2011) Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr 52:90–95PubMedCrossRef Luoto R, Kalliomaki M, Latinen K, Delzene NM, Cani PD, Salminen S, Isolauri E (2011) Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr 52:90–95PubMedCrossRef
21.
Zurück zum Zitat Pecile P, Miorin E, Romanello C, Falleti E, Valent F, Giacomuzzi F, Tenore A (2004) Procalcitonin: a marker of severity of acute pyelonephritis among children. Pediatrics 114:e249–e254PubMedCrossRef Pecile P, Miorin E, Romanello C, Falleti E, Valent F, Giacomuzzi F, Tenore A (2004) Procalcitonin: a marker of severity of acute pyelonephritis among children. Pediatrics 114:e249–e254PubMedCrossRef
22.
Zurück zum Zitat Jantausch BA, O’Donnell R, Wiedermann BL (2000) Urinary interleukin-6 and interleukin-8 in children with urinary tract infection. Pediatr Nephrol 15:236–240PubMedCrossRef Jantausch BA, O’Donnell R, Wiedermann BL (2000) Urinary interleukin-6 and interleukin-8 in children with urinary tract infection. Pediatr Nephrol 15:236–240PubMedCrossRef
23.
Zurück zum Zitat Galanakis E, Bitsori M, Dimitriou H, Giannakopoulou C, Karkavitsas NS, Kalmanti M (2007) Serum and urine interleukin-6 and transforming growth factor-beta1 in young infants with pyelonephritis. Int Urol Nephrol 39:581–585PubMedCrossRef Galanakis E, Bitsori M, Dimitriou H, Giannakopoulou C, Karkavitsas NS, Kalmanti M (2007) Serum and urine interleukin-6 and transforming growth factor-beta1 in young infants with pyelonephritis. Int Urol Nephrol 39:581–585PubMedCrossRef
Metadaten
Titel
Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood
verfasst von
Evanthia A. Tsalkidou
Emmanouel Roilides
Stefanos Gardikis
Gregory Trypsianis
Alexandros Kortsaris
Athanasios Chatzimichael
Ioannis Tentes
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 7/2013
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2432-9

Weitere Artikel der Ausgabe 7/2013

Pediatric Nephrology 7/2013 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.